文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

胰腺癌胰切除术后经验性生存结局的动态分析

A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma.
PubMed 文献 · Surgery · 2022-12-28

研究纳入2000年至2015年7月连续接受胰切除术的1,048例胰腺导管腺癌患者,中位随访30.4个月,计算1至5年经验性生存率并动态分析预后因素。中位生存30.4个月,5年经验性生存率27.5%;landmark分析显示基线预后因素随时间推移失去独立预测作用,早期术后存在显著未观察异质性。

要点

  • 胰切除术后5年经验性生存率为27.5%,中位生存30.4个月
  • 长期生存者中25.7%为R1切除、28.8%为N2病变
  • 基线预后因素随时间推移预测能力下降,早期未观察异质性显著

核心结论

  • 胰切除术后5年经验性生存率为27.5%,动态分析显示预后变量结构随时间变化,未观察肿瘤特征影响显著。

研究设计与样本

  • 2000年至2015年7月连续接受胰切除术的胰腺导管腺癌患者,共1,048例。
  • 全队列中位随访30.4个月,生存者中位随访97.2个月。
  • 采用多变量模型分析长期生存(≥5年)相关因素,通过landmarking进行生存与复发的动态分析,并用frailty模型估计未观察异质性贡献。

主要发现

  • 中位生存30.4个月,1至5年经验性生存率分别为85.5%、59.6%、43.2%、32.1%、27.5%。
  • 良好病理特征与5年生存相关,但长期生存者中25.7%接受R1切除、28.8%有N2病变。
  • 中位无复发生存17.2个月。
  • landmark分析中基线预后因素随时间失去效力,在4年和5年存活患者集中未发现独立生存预测因素。
  • 术后早期存在显著未观察异质性。

关键数值与推荐

  • 5年经验性生存率27.5%,中位生存30.4个月,中位无复发生存17.2个月。
  • 1至5年经验性生存率分别为85.5%、59.6%、43.2%、32.1%、27.5%。
  • 长期生存者中R1切除占25.7%,N2病变占28.8%。

临床怎么用

  • 向患者交代胰切除术后经验性5年生存率约27.5%,并说明长期生存者仍可存在R1切除或N2病变。
  • 术后随访中注意基线预后因素的预测效力随时间减弱,早期需关注未观察肿瘤特征的影响。

局限性

  • 单中心连续病例数据,随访时间跨度长,可能存在治疗与分期变迁的影响。
  • 未观察异质性通过frailty模型估计,具体肿瘤生物学特征未被直接测量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma may be biased by right-censoring. We herein analyzed a large dataset with no censored events for up to 5 years and dynamically investigated the impact of known prognostic factors, accounting for unobserved tumor characteristics. METHODS: Consecutive patients undergoing pancreatectomy from 2000 to July 2015 were included. The 1- to 5-year empirical survival rates were calculated, and factors associated with long-term survival (≥5 years) were analyzed using multivariable models. Dynamic analyses of survival and recurrence were conducted through landmarking, and the contribution of unobserved heterogeneity was estimated using frailty models. RESULTS: The study population included 1,048 patients. The median follow-up was 30.4 months in the whole cohort and 97.2 months in survivors. The median survival was 30.4 months, with empirical 1- to 5-year rates of 85.5%, 59.6%, 43.2%, 32.1%, and 27.5%. A favorable pathological profile was associated with 5-year survival, albeit 25.7% of long-survivors received an R1 resection, and 28.8% had N2 disease. The median recurrence-free survival was 17.2 months. At landmark analyses, baseline prognostic lost strength over time, with no independent predictors of survival being identified in the sets of patients alive at 4 and 5 years. There was a significant amount of unobserved heterogeneity in the early postoperative period. CONCLUSION: The 5-year post-pancreatectomy empirical survival was 27.5%. Dynamic analyses showed a time-varying structure of prognostic variables and a substantial impact of unobserved tumor characteristics that may drive the disease course under the selective pressure of surgical resection and adjuvant chemotherapy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Malleo G, Maggino L, Lionetto G, et al. A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Surgery. 2022. PMID: 36585320. doi:10.1016/j.surg.2022.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。